IDXX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IDXX is not a strong buy right now for a beginner long-term investor who wants to deploy capital immediately. The business is fundamentally solid and Q4 2025 results were strong, but the current setup is mixed: technicals are bearish, analysts have been cutting targets, and the stock is entering earnings with a cautious outlook. At $560.8 pre-market, I would not call this a clear buy today; the better call is to hold and wait for either a better entry or post-earnings confirmation.
The short-term trend is weak. MACD histogram is negative and expanding, RSI at 42.7 shows neutral-to-soft momentum, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock is below/within a downtrend structure. The pre-market price of 560.8 is still below the pivot at 569.651, with immediate support at 550.357 and resistance at 588.946. Near-term pattern analysis suggests only modest upside expectations over the next day/week/month, which does not support an urgent entry.
Hedge funds have been buying aggressively, with buying amount up 764.05% over the last quarter. Q4 2025 financials were strong: revenue grew 14.28% YoY, net income rose 14.82% YoY, EPS increased 17.56% YoY, and gross margin improved to 60.35%. The company also has a structurally attractive business tied to pet health and diagnostics, and Citi noted the long-term pet humanization trend remains supportive. Earnings are scheduled for 2026-05-05 pre-market, which could become a catalyst if guidance is stronger than expected.
Analyst sentiment has weakened: UBS cut its target to $640 from $730 and turned more cautious on softer macro conditions and declining vet visit trends; Citi initiated Neutral with $650; Piper Sandler and UBS both lowered targets earlier; and several firms describe the outlook as balanced or underwhelming. No major news in the last week means there is no fresh positive catalyst. Technicals are bearish, and the stock is facing earnings soon with the Street expecting EPS of 3.42 versus the prior quarter's strong but already known results.
In Q4 2025, IDEXX delivered solid growth: revenue increased to $1.0906B, up 14.28% YoY; net income rose to $248.2M, up 14.82% YoY; EPS increased to $3.08, up 17.56% YoY; and gross margin improved to 60.35%, up 0.92 percentage points YoY. This shows healthy operating momentum in the latest reported quarter, specifically Q4 2025.
Analyst ratings have trended more cautious recently. UBS lowered its target from $730 to $640 and kept Neutral, citing softer macro conditions and weaker vet visit trends. Citi initiated coverage at Neutral with a $650 target and called animal health cautiously optimistic. Stifel still has Buy but cut its target to $675 from $775, saying it is more of a second-half story. Piper Sandler and UBS also reduced targets earlier, while Barclays remains Overweight but cut to $800 from $850 after guidance underwhelmed. Wall Street is split, but the overall tone is cautious-to-neutral rather than strongly bullish.
